Fenofibrate Shortage: What Providers and Prescribers Need to Know in 2026

Fenofibrate remains one of the most commonly prescribed fibrate agents in the United States, used by millions of patients for hypertriglyceridemia and mixed dyslipidemia. While no active FDA shortage has been declared as of 2026, providers are increasingly fielding patient concerns about pharmacy-level stock-outs and questions related to the October 2025 FDA labeling update. This briefing summarizes the clinical and practical landscape for prescribers.

Current Availability Status: No FDA Shortage, But Localized Gaps Persist

As of early 2026, fenofibrate does not appear on the FDA Drug Shortage Database. Generic fenofibrate is manufactured by multiple companies, providing national supply redundancy. However, several factors continue to cause localized pharmacy-level stock-outs that patients report as a shortage:

• Formulation complexity: Fenofibrate is marketed in more than ten strength variations across two forms (tablet and capsule), with different food requirements and brand names. Availability varies significantly by specific formulation.
• Pharmacy contracting: Individual pharmacies source from a single preferred generic manufacturer. When that manufacturer faces a delay or quality hold, the pharmacy may run out before its next shipment, even when other manufacturers have adequate supply.
• Increased demand: Hypertriglyceridemia prevalence is rising in parallel with metabolic syndrome and obesity rates. Growing patient volume for fenofibrate can strain local pharmacy inventory.

The October 2025 FDA Labeling Update: Clinical Implications

In October 2025, the FDA revised fenofibrate's prescribing information in response to a petition from HealthyWomen. The key changes include:

• Explicit statement that fenofibrate did not reduce cardiovascular disease morbidity or mortality in two large, randomized controlled trials (FIELD, 2005; ACCORD Lipid, 2010)
• Highlighted increased risk of rhabdomyolysis when fibrates are used with statins
• Narrowed the indication to reducing elevated LDL-C in adults with primary hyperlipidemia when recommended LDL-C-lowering therapies cannot be used

The labeling update does not remove any previously approved indications and does not constitute a recall. Fenofibrate remains on-label for primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia. However, prescribers should review current ACC/AHA and ADA guidelines to ensure their use of fenofibrate is consistent with updated evidence and labeling.

Clinical Guidance: Which Patients Should Stay on Fenofibrate?

Based on current evidence and guidelines, fenofibrate remains a reasonable choice for:

• Patients with severe hypertriglyceridemia (TG ≥ 500 mg/dL) at risk for pancreatitis — fibrates remain the drug of choice in this setting
• Patients with atherogenic dyslipidemia (low HDL, high TG, high LDL) who have inadequate response to statin therapy — fenofibrate is preferred over gemfibrozil in this population due to lower myopathy risk
• Patients with type 2 diabetes and atherogenic dyslipidemia — subgroup analyses from ACCORD suggest possible microvascular benefit
• Patients with gout and high triglycerides — fenofibrate's uricosuric properties provide added benefit

Prescribing Considerations When Fenofibrate Is Unavailable

If a patient cannot fill fenofibrate at their pharmacy, consider these clinical options:

• Prescribe a different fenofibrate strength: A quick e-prescribe to an equivalent dose in a different strength (e.g., switching from 160 mg to 145 mg or 134 mg) may resolve the stock issue immediately. Bioequivalence between formulations varies; verify before switching.
• Switch to fenofibric acid (Trilipix generics): The delayed-release capsule formulation is therapeutically similar and may have different pharmacy stock status.
• Gemfibrozil (if no statin): 600 mg twice daily is appropriate for patients not on statin therapy. The gemfibrozil-statin combination is associated with a substantially higher risk of myopathy and is generally contraindicated.
• Prescription omega-3 fatty acids: Icosapentaenoic acid (Vascepa 4 g/day) or omega-3-acid ethyl esters (Lovaza 4 g/day) for patients with severe hypertriglyceridemia, especially those on statins. Vascepa has additional MACE data from the REDUCE-IT trial.

A Tool to Help Your Patients Find Fenofibrate in Stock

When patients struggle to fill prescriptions, it increases the risk of treatment gaps and medication non-adherence. medfinder for providers helps bridge that gap. You or your staff can direct patients to medfinder, where they provide their medication details and location, and medfinder calls pharmacies in their area to identify which ones have the medication in stock. Results are texted to the patient. This reduces prescription abandonment and helps patients stay on therapy during localized availability gaps.

Key Takeaways for Providers

• Fenofibrate has no active FDA shortage in 2026; localized stock-outs are a pharmacy-level issue
• The October 2025 labeling update clarifies cardiovascular evidence but does not restrict current prescribing
• Prescribing a different fenofibrate strength or formulation often resolves the availability issue quickly
• Avoid gemfibrozil in statin-treated patients; fenofibrate or omega-3s are the preferred alternatives
• Direct patients to medfinder to help them locate their specific formulation at a pharmacy near them